Updates in Lymphoma From Recent Congresses

Slides:

Advertisements

Similar presentations

Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.

Advertisements

Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Ruan J et al. Proc ASH 2013;Abstract 247.

Fujiwara H et al. Proc ASH 2015;Abstract 181.

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

Innovations and Issues in Mantle Cell Lymphoma

Relapsed/Refractory Follicular Lymphoma Conundrums

Updates in Hodgkin Lymphoma

Hot Topics in Lymphoma Supportive Care

Discussion Outline Cells of the Immune System.

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Peripheral T-Cell Lymphoma in 2013

Prolonging Progression-Free Survival in Follicular Lymphoma

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

Current and Future Goals in the Treatment of Relapsed CLL

Goals of Therapy in Relapsed CLL

Advances in Lymphoma.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Updates in Follicular Lymphoma

Challenges in Managing Progressive Multiple Sclerosis

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Novel and Emerging Approaches to Treating CLL

Activity Goals. Activity Goals Case Presentation.

Treatment Decisions in Chemorefractory Follicular Lymphoma

Management Challenges in CLL

Treating mRCC After Initial Antiangiogenic Therapy:

Jonathan W. Friedberg M.D., M.M.Sc.

The Biology Behind BCL2 as a Target in Myeloma

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Recent Advances in the Treatment of Lymphoma

Advances in Multiple Myeloma

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma

Navigating New Oral Treatment Algorithms in CLL

Targeting BTK Signaling in B-Cell Malignancies

Managing Adverse Events With New Oral Therapies in CLL

Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

Optimizing Outcomes and Managing Adverse Events in CLL

Minimal Residual Disease in CLL

Mutational Testing to Select Novel Targeted Therapies in AML

Personalized Therapy in Relapsed or Refractory CLL

How to Select Therapy In Newly Diagnosed CLL

Interprofessional Approaches: Managing AEs of Novel Therapies for NHL/CLL.

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

PARP Inhibitors.

Non-Chemotherapy Combinations in CLL

Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

Assessing New Paradigms in CLL: MRD Negativity

FDA-Approved PI3K Inhibitors for CLL and FL

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Managing CLL With BTK Inhibitors

Ahmadi T et al. Proc ASH 2011;Abstract 266.

CLL - When to treat, how to treat

Oral Treatment Strategies in CLL

Novel Therapeutics in MS

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Foroud shahbazi Pharm.D

How to Select Therapy in Relapsed/Refractory CLL

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

Targeting Apoptosis in AML

PAH Pathways: What Do the Data Tell Us?”

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Changing Paradigms in Relapsed/Refractory Indolent NHL

Treatment Initiation and Selection in Newly Diagnosed CLL

Presentation transcript:

Updates in Lymphoma From Recent Congresses

Therapeutic Targets in CLL

Venetoclax in Patients With 17p Deletion

Venetoclax in Patients With 17p Deletion (cont)

Bendamustine Plus Obinutuzumab

Ibrutinib Plus Ublituximab

Updates in Lymphoma From Recent Congresses

EZH2 Inhibitor Tazemetostat

EZH2 Inhibitor Tazemetostat (cont)

Gene Expression Profiling in the Prediction of Disease Progression

Causes of Death in FL

Causes of Death in FL (cont)

FL Transformation

Cumulative Incidence by Rituximab Use (n = 6340)

Pembrolizumab Plus Rituximab

Pembrolizumab Plus Rituximab: Results

Lenalidomide Plus Rituximab

Lenalidomide Plus Rituximab (cont)

Updates in Lymphoma From Recent Congresses

The SCHOLAR-1 Study

CAR T-Cell Therapy: CTL019

CAR T-Cell Therapy: ZUMA-1 Trial of KTE-C19

Clinical Conclusions

Pembrolizumab For Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma

Updates in Lymphoma From Recent Congresses

The BRIGHT Trial: 5-Year Follow-Up

The BRIGHT Trial: 5-Year Follow-Up (cont)

Single-Agent Lenalidomide in Relapsed or Refractory MCL

Ibrutinib vs Temsirolimus

Combining Ibrutinib With Venetoclax

Abbreviations

Abbreviations (cont)

Abbreviations (cont)